4 assets in Tumor Of Uterus

Therapeutic assets addressing Tumor Of Uterus, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Fulvestrant Tumor Of Uterus	Atavistik Bio, Inc	P2	B (60)
Trastuzumab Tumor Of Uterus	Seagen, a wholly owned subsidiary of Pfizer	P2	CCC (53)
Tucatinib Tumor Of Uterus	Seagen, a wholly owned subsidiary of Pfizer	P2	CCC (53)
Atv-1601 Tumor Of Uterus	Atavistik Bio, Inc	P1	CC (43)